Welcome to our dedicated page for Theravance Bioph SEC filings (Ticker: TBPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Theravance Biopharma, Inc. filings document operating results, material events, governance matters, and portfolio disclosures for a Cayman Islands biopharmaceutical issuer. Form 8-K reports furnish quarterly and annual financial updates, YUPELRI collaboration revenue, business updates, Regulation FD materials, and financial-condition disclosures tied to the company’s therapeutics business.
The filing record also covers product and intellectual-property matters, including a Hatch-Waxman settlement resolving ANDA patent litigation involving YUPELRI® (revefenacin) inhalation solution. Other disclosures address the ampreloxetine Phase 3 CYPRESS outcome, costs associated with organizational restructuring and program wind-down activities, annual general meeting voting matters, director elections, and proxy governance.
Sawaf Aziz reported acquisition or exercise transactions in this Form 4 filing.
Theravance Biopharma, Inc. reported that its SVP & Chief Financial Officer, Aziz Sawaf, received a grant of 37,500 Ordinary Shares on April 1, 2026. The shares were awarded at a stated price of $0.00 per share, reflecting compensation rather than a market purchase.
Following this award, Mr. Sawaf directly holds 353,623 Ordinary Shares of Theravance Biopharma. This filing records a stock-based compensation grant to a senior executive, not an open-market buy or sell transaction.
Grimaud Brett A. reported acquisition or exercise transactions in this Form 4 filing.
Theravance Biopharma, Inc. executive Brett A. Grimaud, SVP, General Counsel and Secretary, received a grant of 37,500 Ordinary Shares on April 1, 2026. The shares were awarded at a stated price of $0.00 per share as compensation rather than a market purchase. Following this grant, his direct holdings increased to 371,949 Ordinary Shares, according to the filing.
Farnum Rhonda reported acquisition or exercise transactions in this Form 4 filing.
Theravance Biopharma, Inc. reported that SVP, Commercial & Medical Affairs Rhonda Farnum received a grant of 18,750 Ordinary Shares of the company on April 1, 2026. The shares were granted at a stated price of $0.00 per share as compensation rather than a market purchase.
Following this award, Farnum directly holds a total of 251,449 Ordinary Shares of Theravance Biopharma, Inc., reflecting an increase in her equity-based compensation stake in the company.
Theravance Biopharma, Inc. announced a settlement of patent litigation over its YUPELRI® (revefenacin) inhalation solution. Theravance and its partner Mylan granted Mankind Pharma a royalty-free, non-exclusive license to sell a generic YUPELRI in the U.S. starting on the Licensed Launch Date of April 23, 2039, subject to customary exceptions.
The agreement resolves all pending Hatch-Waxman patent disputes related to YUPELRI. The settlement will be reviewed by the U.S. Department of Justice and the Federal Trade Commission, as required for patent settlements involving branded and generic drug makers.
Weiss Asset Management and related entities filed Amendment No. 3 to their Schedule 13D on Theravance Biopharma, Inc. The filing reports beneficial ownership of 7,457,060 ordinary shares, representing 14.5% of Theravance’s outstanding shares, based on 51,492,924 shares outstanding as of February 28, 2026.
The filing notes that 4,628,074 shares, or 9.0% of the company, are held by BIP, and 2,828,986 shares, or 5.5%, are held by BGO. Weiss Asset Management LP serves as investment manager to both funds, and Andrew M. Weiss, through WAM GP LLC, has power to vote and dispose of these shares. The reporting persons state they have not effected any transactions in Theravance shares during the past 60 days.
Theravance Biopharma reports a pivotal shift in its business following mixed 2025 developments. YUPELRI® net sales rose 12% to $266.6 million, triggering a $25.0 million milestone from Viatris and reaching record annual sales and brand profitability.
The company sold its remaining TRELEGY® royalty interest to GSK for $225.0 million and received a $50.0 million TRELEGY milestone in 2026, while up to $100.0 million in additional TRELEGY milestones remain available. However, Phase 3 ampreloxetine (CYPRESS) failed its primary endpoint, leading to wind-down of that program.
In response, Theravance is implementing a restructuring that will wind down R&D, significantly reduce G&A, and is expected to cut operating expenses by about 60% versus 2025, delivering roughly $70 million in annualized savings from Q3 2026. A Strategic Review Committee is urgently evaluating alternatives, including a potential sale of the company, to maximize shareholder value.
Theravance Biopharma reported a sharp turnaround for 2025, with revenue rising to $107.5M from $64.4M and net income improving to $105.9M from a $56.4M loss in 2024. Q4 revenue was $45.9M and net income $61.0M.
YUPELRI® remained the core driver, with 2025 net sales of $266.6M (Viatris-reported) versus $238.6M in 2024. The company is winding down R&D, cutting G&A about 50%, and expects operating expenses to fall about 60% from 2025’s $111.1M, targeting $60–70M of annualized cash flow from Q3 2026.
A Board Strategic Review Committee of independent directors, advised by Lazard, is urgently evaluating alternatives, including a potential sale of the company, following the CYPRESS study not meeting its primary endpoint and the wind-down of the ampreloxetine program.
Theravance Biopharma, Inc. senior executive Rhonda Farnum, SVP, Commercial & Medical Affairs, sold a total of 31,067 ordinary shares of TBPH in open-market transactions on March 16, 2026, at prices ranging from $13.755 to $14.01. After these sales, she directly owns 232,699 ordinary shares of the company.
Theravance Biopharma reported that its Phase 3 CYPRESS trial of ampreloxetine in neurogenic orthostatic hypotension did not meet the primary OHSA composite endpoint, and the program will be wound down. The Board’s Strategic Review Committee is accelerating its evaluation of alternatives, including a possible sale of the company, with no assurance any transaction will occur.
The company announced a major restructuring that will eliminate its R&D organization, reduce G&A by about 50%, and cut operating expenses by roughly 60%, or about $70 million, impacting around half of the workforce. Management expects these actions, together with YUPELRI revenue, to support approximately $60–$70 million of annualized cash flow starting in Q3 2026.
Theravance highlighted cash of $326.5 million as of December 31 2025, expected cash of about $400 million at the end of Q1 2026 after receiving a $25 million YUPELRI milestone and a $50 million TRELEGY milestone, and a potential additional $100 million TRELEGY milestone tied to 2026 global sales. YUPELRI U.S. net sales reached $266.6 million in 2025, up 12% year over year.